Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2021 08:00 ET | Source: eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
August 25, 2021 19:18 ET | Source: eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
August 04, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer,...
July 22, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
July 16, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (“STRIs”) for the treatment of cancer, announced...
June 14, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR Therapeutics to Present at JMP Securities 2021 Life Sciences Conference

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (“eFFECTOR”), a biopharmaceutical company focused on pioneering the development of selective translation regulation...
June 09, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial

SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
May 27, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies

Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR’s pipeline advancement through multiple clinical...
May 04, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR and Quantitative Biosciences Institute (QBI) at UCSF Receive $5.0 Million from DARPA to Evaluate Zotatifin in COVID-19

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today...
January 07, 2021 08:00 ET | Source: eFFECTOR Therapeutics

eFFECTOR Appoints Mike Byrnes as Chief Financial Officer

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right